ADIPOQ and ovarian cancer: Other authors showed that women affected by ovarian cancer with a low leptin/adiponectin ratio had statistically longer progression-free survival times (using Kaplan–Meier survival estimates) than those with a higher leptin/adiponectin ratio [124].